|
FDA Restricts IRB Following Two Failed Inspections
The FDA has halted approval of new trials and enrollment in ongoing studies reviewed by the investigational review board (IRB) BioMed after two negative assessments of the board’s work.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives